Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Novo Nordisk has taken another step towards expanding ... Corvidia’s lead drug candidate – interleukin-6 inhibitor ziltivekimab (formerly COR-001) – is being developed as a therapy for ...

Currently, in Phase III trials for patients with chronic kidney disease, Ziltivekimab became part of Novo Nordisk's portfolio after the company acquired Corvidia Therapeutics in June 2020 for USD ...